Inventaire - your friends and communities are your best library

JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer

author

Takayuki Yoshino

Atsushi Ohtsu

Masahito Kotaka

Katsunori Shinozaki

Tetsuo Touyama

Dai Manaka

Takanori Matsui

Kiyoshi Ishigure

Junichi Hasegawa

Keiji Inoue

Koichi Goto

Akinori Takagane

Yoshinori Munemoto

Yoshihiko Maehara

published in: Cancer Chemotherapy and Pharmacology

date of publication: 2019-09-23

main subject: colon cancer

Cites articles 23

Date

Title

Authors

2018-03-01

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Thierry André, Jeffrey A Meyerhardt, Lindsay Anne Renfro, Takayuki Yoshino, Dewi Vernerey
2018-04-17

A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.

Satoshi Teramukai
2017-03-27

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

Yutaka Saito, Kenjiro Kotake, Yoshinori Ito, Shinji Tanaka, Shiro Oka, Toshiaki Tanaka, Takayuki Yoshino, Narikazu Boku, Toshiaki Watanabe, Kei Muro, Yoichi Ajioka, Yojiro Hashiguchi, Tetsuya Hamaguchi, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Yusuke Kinugasa, Keiko Nemoto Murofushi, Takako Eguchi Nakajima, Yoshiharu Sakai, Keisuke Uehara, Kentaro Yamazaki, Takahiro Fujimori, Michio Itabashi, Nobuo Koinuma, Genichi Nishimura, Yuh Sakata, Toshiharu Yamaguchi, Japanese Society for Cancer of the Colon and Rectum
2017-10-24

Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
2015-05-16

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)

Koji Oba, Takayuki Yoshino, Atsushi Ohtsu, Masahito Kotaka, Katsunori Shinozaki, Tetsuo Touyama, Dai Manaka, Takanori Matsui, Kiyoshi Ishigure, Junichi Hasegawa, Keiji Inoue, Koichi Goto, Shigetoyo Saji
2015-08-17

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Nathan P. Staff
2015-09-07

Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
2014-06-18

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).

Kenjiro Kotake, Eiji Nakatani
2014-06-20

Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: f

Shigeki Yamaguchi
2014-12-31

Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study

Ismail Gögenur
2013-06-17

Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry
2013-08-01

Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors
2013-01-01

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status

Thierry André, Roberto Labianca, Daniel J. Sargent, Jeffrey A Meyerhardt, Takayuki Yoshino, Atsushi Ohtsu, Alberto Sobrero, Timothy Iveson, Ioannis Sougklakos, Axel Grothey
2013-10-01

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Roberto Labianca, Dirk Arnold, ESMO Guidelines Working Group
2012-04-02

Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation.

Nicholas P. West, Philip Quirke
2012-05-08

Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.

Reena Cecchini, Greg Yothers, Kelley Kidwell, Patricia Ganz
2010-10-12

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
2009-05-04

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

Greg Yothers
2009-05-18

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

Aimery de Gramont, Josep Tabernero Caturla
2007-03-01

Lymph node evaluation and survival after curative resection of colon cancer: systematic review
2007-04-30

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07

Reena Cecchini, Patricia Ganz
2006-07-03

Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up

Massimo Leandri
2004-06-01

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer

Josep Tabernero Caturla, Thierry André

Article - wd:Q90247055

Welcome to Inventaire

the library of your friends and communities

learn more